Glioblastoma: Molecular analysis and its clinical implications

Carlos A. Castañeda, Sandro Casavilca, Enrique Orrego, Pamela García-Corrochano, Pedro Deza, Hugo Heinike, Miluska Castillo, Carolina Belmar-Lopez, Luis Ojeda

Research output: Contribution to journalArticle

Abstract

© 2015 Instituto Nacional de Salud. All rights reserved. Glioblastoma (GB) is the most common and most lethal primary brain tumor. Epidemiologic information indicate that its incidence is lower in Hispanic race. Surgery is the only curative strategy and has recently introduced new strategies that increase resection rates. The use of concurrent chemotherapy with radiotherapy improves survival of patients but is associated with toxicity. Improved understanding of molecular biology of GB allows the identification of predictive biomarkers of response and prognosis as well as therapeutic targets for the development of new therapeutic strategies. Among biomarkers are currently available 1p /19q codeletion, IDH mutation and O6-methylguanine DNAmethyltransferase promoter methylation. The identification therapeutic targets enables the development of new drugs and their evaluation in clinical trials, but none has been prospectively validated in phase III clinical trials.
Original languageAmerican English
Pages (from-to)316-325
Number of pages10
JournalRevista Peruana de Medicina Experimental y Salud Publica
DOIs
StatePublished - 1 Apr 2015
Externally publishedYes

Fingerprint Dive into the research topics of 'Glioblastoma: Molecular analysis and its clinical implications'. Together they form a unique fingerprint.

  • Cite this

    Castañeda, C. A., Casavilca, S., Orrego, E., García-Corrochano, P., Deza, P., Heinike, H., Castillo, M., Belmar-Lopez, C., & Ojeda, L. (2015). Glioblastoma: Molecular analysis and its clinical implications. Revista Peruana de Medicina Experimental y Salud Publica, 316-325. https://doi.org/10.17843/rpmesp.2015.322.1627